Related Experiment Video
Updated: Feb 7, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised
J W G Derksen1, D Martins-Branco2, A Valachis3
1Julius Center for Health Sciences and Primary Care, Department of Epidemiology and Health Economics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Background:
The role of real-world evidence (RWE) for clinical efficacy regulatory evaluation remains unclear. We aimed to assess and describe the reported use of RWE for clinical efficacy evaluation of authorised targeted therapies for treatment of solid malignancies in Europe.
Design:
We studied all authorised indications of targeted therapies for the treatment of solid malignancies granted by the European Medicines Agency between 2018 and 2022. Data were retrieved in March 2023 from European Public Assessment Reports (EPARs). We evaluated the frequency of RWE use for clinical efficacy evaluation and its role based on the reported information in the EPAR, and assessed characteristics and risk of bias of published studies.
Results:
Out of 75 authorised indications identified, most related to the treatment of patients with lung (21.3%) or breast (20.0%) cacer, and to advanced settings (89.3%). The use of RWE for clinical efficacy evaluation was reported in the EPAR of 16 (21.3%) indications, tending to increase overtime (15.0%-35.7% in 2018-2022). RWE was more frequently considered in lung (37.5%) and breast (33.3%) cancer indications, for antibody-drug conjugates (60.0%), and conditional approvals (46.7%). We classified RWE's role as 'supportive' confirmatory evidence in 12 of 16 (75.0%) indications. RWE studies were mostly analytical (57.1%), non-international (92.9%), retrospective cohort studies (57.1%), and originated from the United States (78.6%). High or serious risk of bias was identified in different domains of most studies assessed.
Conclusions:
RWE was reported to be used for clinical efficacy regulatory evaluation in 21% of targeted therapy indications for solid malignancies, with an increasing trend over time.
Insights
Real-world evidence (RWE) was used in 21% of European regulatory evaluations for targeted cancer therapies, showing an increasing trend. Most RWE served as supportive evidence, though studies often had a high risk of bias.
Area of Science:
- Oncology
- Regulatory Science
- Health Economics and Outcomes Research
Background:
- The precise role of real-world evidence (RWE) in the regulatory assessment of clinical efficacy for targeted therapies remains incompletely defined.
- This study focuses on targeted therapies authorized in Europe for solid tumors.
Purpose of the Study:
- To assess and describe the reported utilization of RWE for the clinical efficacy evaluation of authorized targeted therapies for solid malignancies in Europe.
- To analyze the frequency, role, characteristics, and risk of bias of RWE used in regulatory submissions.
Main Methods:
- Systematic review of European Public Assessment Reports (EPARs) for targeted therapies approved by the European Medicines Agency (EMA) between 2018 and 2022.
- Data retrieval and analysis conducted in March 2023.
- Evaluation of RWE frequency, role, study design, origin, and risk of bias.
Main Results:
- Real-world evidence (RWE) was reported in the EPARs of 16 out of 75 (21.3%) authorized indications, with a rising trend observed from 2018 to 2022.
- RWE was more frequently utilized for lung and breast cancer indications, antibody-drug conjugates, and conditional approvals.
- In most cases (75%), RWE functioned as supportive or confirmatory evidence, primarily from retrospective, non-international, analytical studies, predominantly originating from the US, and often exhibiting a high risk of bias.
Conclusions:
- Real-world evidence (RWE) is increasingly being incorporated into the regulatory evaluation of targeted therapies for solid tumors in Europe.
- While RWE plays a supportive role, the methodological quality and risk of bias in existing studies necessitate careful consideration during regulatory decision-making.
Related Concept Videos
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders
Reporter Genes
Introduction to Documentation and Reporting
Nursing documentation records essential information and details regarding a patient's care and treatment in written or electronic form. It is a critical aspect of nursing practice that involves documenting assessments, interventions, outcomes, and other relevant details about a patient's health status.
Documentation maps the patient's health journey by creating a comprehensive...

